Article
Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder.
Molecular psychiatry - 1 Sept 2016
Song J, Bergen S E, Di Florio A, Karlsson R, Charney A, Ruderfer D M, Stahl E A, Chambert K D, Moran J L, Gordon-Smith K, Forty L, Green E K, Jones I, Jones L, Scolnick E M, Sklar P, Smoller J W, Lichtenstein P, Hultman C, Craddock N, Landén M, Smoller Jordan W, Perlis Roy H, Lee Phil Hyoun, Castro Victor M, Hoffnagle Alison G, Sklar Pamela, Stahl Eli A, Purcell Shaun M, Ruderfer Douglas M, Charney Alexander W, Roussos Panos, Michele Pato Carlos Pato, Medeiros Helen, Sobel Janet, Craddock Nick, Jones Ian, Forty Liz, Florio Arianna Di, Green Elaine, Jones Lisa, Gordon-Smith Katherine, Landen Mikael, Hultman Christina, Jureus Anders, Bergen Sarah, McCarroll Steven, Moran Jennifer, Smoller Jordan W, Chambert Kimberly, Belliveau Richard A
Abstract excerpt
Lithium is the mainstay prophylactic treatment for bipolar disorder (BD), but treatment response varies considerably across individuals. Patients who respond well to lithium treatment might represent a relatively homogeneous subtype of this genetically and phenotypically diverse disorder. Here, we performed genome-wide association studies (GWAS) to identify (i) specific genetic variations influencing lithium...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
